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ABSTRACT

Clostridium difficile is the most common infectious cause of nosocomial diarrhea,
affecting thousands of patients annually and exacting enormous costs on the U.S. health
care system. Early diagnosis is critical to prevent transmission and reduce morbidity and
mortality, yet sensitive and specific diagnostic tests with a quick turnaround time are
lacking. The objective of this study was to determine if a new commercially available
real time polymerase chain reaction (PCR) test would prove more rapid, sensitive and
specific than standard methods for the diagnosis of C. difficile infection (CDI). BD
GeneOhm™ Cdiff assay, a real-time PCR assay for detection of C. difficile toxin B
(tcdB) gene, was compared with Tox A/B II™ ELISA and a two-step algorithm which
includes C. Diff Chek-60™ Glutamate Dehydrogenase (GDH)-antigen assay followed by
cytotoxin neutralization. Four-hundred liquid or semisolid stools submitted for diagnostic
C. difficile testing were selected: 200 GDH antigen-positive and 200 GDH antigennegative. All samples were tested by the C. Diff Chek-60™ GDH antigen, cytotoxin
neutralization, Toxin A/B II™ ELISA, and BD GeneOhm™ Cdiff assay. Discrepant
specimens were tested by toxigenic culture as an independent gold standard. Chart
review was performed on patients with discrepant specimens. As BD GeneOhm™ Cdiff
assay was not FDA-cleared at the time of study, PCR results were not clinically reported.
Of 200 GDH-positive samples, 71 were positive by Tox A/B II, 88 were positive by the
two-step method, 93 were positive by PCR, and 96 were positive by GDH-antigen only.
Of 200 GDH-negative samples, 3 were positive by PCR only. Toxigenic culture was
performed on 41 samples with discrepant results and 39 were culture-positive. After
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culture resolution of discrepants, Tox A/B II detected 70 (66.7%), the two-step method
detected 87 (82.9%), and PCR detected 96 (91.4%) of 105 true positives. The BD GeneOhm™ Cdiff assay was more sensitive in detecting toxigenic C. difficile than Tox A/B II
(p <0.0001); however, the difference between PCR and the two-step method was not
significant (p=0.1237). The BD GeneOhm™ Cdiff assay took a similar amount of time
to perform as the Tox A/B II and was more rapid than the two-step method. Chart review
revealed that 18 patients with cytotoxin-negative, PCR-positive discrepant samples were
given 1-2 days of therapy (n=8), or no treatment at all (n=10). Yet symptoms resolved
and no further C. difficile testing was requested for 13 of 18 patients for 6-8 months after
hospital discharge. Only one patient had a subsequent cytotoxin positive stool submitted
22 days after the study sample was tested. Enhanced sensitivity and rapid turnaround
time make the BD GeneOhm™ Cdiff assay an important advance in the diagnosis of
toxigenic C. difficile infection. The BD GeneOhm™ Cdiff assay is significantly more
sensitive than a commonly-used ELISA toxin assay and has a sensitivity and specificity
comparable to the two-step method. Its turnaround time is similar to ELISA toxin assays
and more rapid than the two-step method. Disadvantages to implementation of BD
GeneOhm™ Cdiff assay include increased cost and potential treatment of asymptomatic
carriers and mild, self-resolving disease.
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INTRODUCTION AND BACKGROUND
Clostridium difficile infection (CDI) is increasing as the most common infectious cause
of nosocomial diarrhea in hospitalized patients in the United States (1). C. difficile
infection (CDI) accounts for 15-25% of all cases of antibiotic-associated diarrhea (2). It is
estimated that approximately half a million cases of CDI occur in the United States per
year and 15,000-20,000 of these patients die from CDI (1). In the U.S., CDI is
responsible for more deaths than all other intestinal infections combined (3). One study
estimated that CDI costs an average of $3600 more per patient with length of stay in the
hospital extended by 3.6 days. When extrapolated, the cost of CDI disease burden to the
United States health care system was $1.1 billion annually (4). In response to this disease
burden, hospitals have had to institute systems of early identification and isolation of C.
difficile- positive patients in order to minimize morbidity and prevent spread to other
patients (5). The effectiveness of early detection depends upon the speed and accuracy of
the laboratory tests, which until now have been suboptimal. Commercial polymerase
chain reaction (PCR) tests are now becoming available, but their performance compared
to current methods has not been established.

Microbiology of Clostridium difficile
C. difficile is an obligately anaerobic gram-positive rod. It forms spores that can remain
in the environment for months and are resistant to the low pH of stomach acid (6, 7).
Spores have been found to be resistant to non-chlorine based cleaning agents and heat of
common hospital laundry cycles, even cross-contaminating bed linens during laundering
(8). Other virulence factors include: adhesins, proteases, and toxin production (1).
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Pathogenesis
Typically C. difficile disease is caused by administration of broad-spectrum antibiotics to
which C. difficile is not susceptible, leading to disruption of normal colonic bacterial
flora and overgrowth of C. difficile after ingestion of spores. Spores germinate and
vegetative forms multiply, after which they adhere to and penetrate the mucous layer
coating colonic epithelium with the aid of proteases, including a hydraluronidase, and
flagella. This then allows the bacteria to adhere to enterocytes via multiple adhesins and
complete the colonization phase (7, 9).

After colonization, C. difficile enters the toxin production phase. Its main virulence
factors are two protein exotoxins, toxin A (enterotoxin) and toxin B (cytotoxin), which
are the largest bacterial single-molecule exotoxins known (6). The toxin A (TcdA) and
toxin B (TcdB) genes are located within a pathogenicity locus that is comprised of five
genes, including TcdC, TcdE, and TcdR which encode regulatory proteins (9).
Production of Toxin A and B is negatively regulated by the TcdC gene locus (10). Both
toxins act similarly by being endocytosed into colonic cells where they disrupt the actin
cytoskeleton and tight junctions, leading to decreased transepithelial resistance, fluid
accumulation and ultimately death of the intestinal epithelium. Toxin B is about 1000
times more potent than toxin A, having 100-fold higher enzymatic activity per toxin
molecule. Both toxins stimulate monocytes to produce TNF and IL-8, leading to
extravasation and tissue infiltration by neutrophils, which in turn cause an inflammatory
response and contribute to mucosal cell destruction and pseudomembrane formation (7,
11).
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Toxins A and B are produced in the late log and stationary phases. Their levels are
impacted by the availability of nutrients, temperature and sub-inhibitory levels of
antibiotics (12). According to one in-vitro study, toxigenic C. difficile showed earlier and
increased rates of toxin production when exposed to sub-MIC concentrations of
vancomycin, metronidazole and linezolid, as compared to controls not exposed to
antibiotics (13).

Toxin B is necessary to produce clinical disease, whereas toxin A alone is insufficient.
TcdA-negative and TcdB-positive strains have been reported (1). Nontoxigenic strains of
C. difficile lack TcdA and TcdB (14). The pathogenicity locus is replaced with a noncoding sequence (1). Patients can be asymptomatically colonized with strains of C.
difficile. There is some evidence to suggest that asymptomatic carriage is associated with
higher levels of IgG against C. difficile toxins and that colonized patients with lower
levels of immunoglobulin are more likely to develop symptomatic disease (4).

A relatively recent epidemiologic occurrence has been the emergence of a hypervirulent
epidemic strain of C. difficile associated with hospital outbreaks in several countries with
high rates of complications and mortality. The strain – labeled BI/NAP1/027 for short –
is restriction endonuclease analysis group BI, pulse-field gel electrophoresis type NAP1,
and polymerase chain reaction ribotype 027. Its unique virulence factors are
characterized by increased levels of toxin A and B; synthesis of a third toxin, binary
toxin; and resistance to fluoroquinolones. The first factor is thought to be largely due to
deletion of the tcdC gene that is a repressor of toxin A and B production. These strains
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produce up to 23-fold more toxin than other strains without the same mutation (9, 15, 16).

Another epidemiologic concern is the question of rising incidence of communityacquired CDI in which patients have no recent history of hospitalization or antibiotic
exposure. Two surveys by the Centers for Disease Control in 2005-2006 found the rates
of community-acquired CDI per 100,000 population in Philadelphia and Connecticut to
be 7.6 and 6.9, respectively (17, 18). An earlier study in Boston found a rate of 7.7 per
100,000 person years with 35% of the study population not having received antibiotics in
the six weeks prior to onset of symptoms (19). While the rate of CDI in the community
is still much lower than in hospitalized patients, infections are increasingly being reported
in populations that were otherwise thought to be at low-risk (1, 11).

Risk Factors for C. difficile Infection
The major risk factors for CDI that have been identified are: broad-spectrum antibiotic
exposure, specifically to clindamycin, cephalosporins, extended-spectrum beta lactams,
and aminopenicillins; prolonged hospitalization (>72 hours); and older age (>65 years)
(1, 2, 9). Other associated risk factors include concomitant use of antacids,
immunosuppressive states or therapy (e.g. methotrexate), and inflammatory bowel
disease (20). There is conflicting evidence about whether or not fluoroquinolones
increase the risk of developing CDI, though BI/NAP1/027 strains have been documented
to be resistant to this antibiotic class (21).
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Signs and Symptoms
The typical clinical presentation of CDI is the onset of watery diarrhea with a typical
foul-smelling odor in a patient who has received broad-spectrum antibiotics and been
hospitalized for greater than 72 hours. Fever and abdominal pain or cramping can also be
present, though they may be absent. Laboratory data may show leukocytosis, presence of
fecal leukocytes, and hypoalbuminemia. The presentation of CDI can range from mild
diarrhea to fulminant colonic failure. Rarely, diarrhea will be absent, as in a patient with
paralytic ileus, particularly in association with narcotics administration (2, 22).

While CDI should be the first entity ruled out in a patient with antibiotic-associated
diarrhea who has been hospitalized >72 hours, the differential diagnosis includes:
antibiotic side effects; failure of colonic flora to catabolize carbohydrates; and other
infectious etiologies such as Staphylococcus aureus (including methicillin-resistant
strains), enterotoxin-producing strains of Clostridium perfringens, Salmonella species,
and Klebsiella oxytoca, though these are rare (23).

Complications
Fulminant or severe complicated CDI includes the development of pseudomembranous
colitis, which can lead to toxic megacolon or bowel perforation, septic shock and even
death. This can necessitate intensive care unit admission and surgical intervention
including colectomy. These complications are rare but when they do occur the costs of
hospitalization are high (1).
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Treatment
For mild, uncomplicated disease, oral metronidazole for 10-14 days is the preferred firstline therapy, primarily because it is more cost-effective.1 In severe or complicated cases,
oral vancomycin is the recommended treatment (24). Intravenous metronidazole is
reserved for patients who cannot take oral medications. One recent randomized, placebocontrolled, double-blind trial stratified by disease severity showed no statistically
significant difference in outcomes for patients with mild CDI treated with oral
metronidazole versus vancomycin. However, for severe disease, oral vancomycin was
shown to achieve a significantly higher cure rate than metronidazole, perhaps secondary
to the higher intra-colonic concentrations achieved as a result of poor systemic absorption
(25). Both metronidazole and vancomycin have been associated with higher rates of
colonization with vancomycin-resistant enterococci (VRE), though this has been
insufficiently studied.

Alternative antimicrobial treatment options that have not been well studied include
rifaximin PO, nitazoxanide PO, and ramoplanin. Adjunct treatments include toxinbinding resins (i.e. tolevamer and cholestyramine), intravenous immune globulin and
probiotics, though evidence for success of these agents is mixed and unclear (20). A
Cochrane review of the use of probiotics in C. difficile treatment found that in only one
study had they been shown to reduce rates of disease recurrence, but otherwise there was
no evidence to support their use as a sole treatment agent (26).

1

According to one estimate by Pepin, et al., a 10-day course of metronidazole costs approximately
$20 whereas a 10-day course of vancomycin is approximately $600.
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Recurrence
Recurrence of CDI is likely due to the persistence of bacterial spores despite high intracolonic concentrations of antibiotic (assuming an oral form of antibiotic has been
previously administered), which then germinate upon discontinuation of therapy.
However, up to half of recurrent cases have been found to be due to re-infection with a
new strain (23). In spite of effective antibiotic therapy, up to 15-25% of patients will
have recurrent disease after completion of treatment (27).

A recent meta-analysis assessing risk factors studied for recurrent CDI reported that only
three factors were significantly associated: continued use of non-C. difficile antibiotics
after diagnosis of CDI, concomitant receipt of antacid medications and older age (28).
However, these are also risk factors for acquisition of primary CDI as well. A more
specific explanation of risk for recurrent CDI was proposed by Kyne and colleagues, who
found that levels of both IgM and IgG against C. difficile toxin A were higher in patients
with only a single episode of CDI than in patients who had experienced recurrent disease.
They suggest that immune response to toxin A confers a protective effect against future
infections, and that failure to produce an anamnestic immune response is a risk factor for
development of recurrent disease (29).

In treatment of recurrent CDI, the following approach has been suggested. Diagnosis of
CDI should always be confirmed by laboratory tests. The first recurrent episode should
be treated as per the guidelines elaborated above according to disease severity. For a
second recurrent episode a taper of vancomycin PO is recommended, which is presumed
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to induce germination of spores. 2 For further recurrent episodes there are many
suggested regimens that can include vancomycin PO (tapered or not) plus an adjunctive
treatment such as cholestyramine, probiotics or IVIG (27). Alternatively, another
antibiotic such as nitazoxanide or rifaximin can be trialed. In severe recalcitrant cases,
fecal transplants via enema from healthy living relatives has showed anecdotal success,
though this procedure carries the risk of transmitting other intestinal infections and has
not been widely studied (23).

Prevention
Interventions which have been shown to reduce incidence of nosocomial CDI include:
timely diagnosis, cessation of offending antibiotic and treatment; prompt reporting of test
results to clinicians and hospital epidemiology; discontinuation of anti-peristaltic
medications when appropriate; placing the patient in isolation with contact precautions
and handwashing station; and thorough cleaning of room after patient discharge with a
bleach-based solution (5).

Diagnosis
Despite the urgent need for early diagnosis of CDI, sensitive and specific commercially
available diagnostic tests with a rapid turnaround time are lacking (30). Available test
methods include:

2

The following taper regimen is suggested: 125 mg q 6 h for 7 days, then 125 mg q 12 h for 7 days,
then 125 mg qd for 7 days, then 125 mg qod for 7 days, and finally 125 mg every 3 days for 7 days.
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Toxigenic Culture.

Culture of stool samples on selective, pre-reduced cycloserine-

cefoxitin-fructose agar, followed by testing for the presence of toxin via ELISA or
cytotoxin neutralization assay, is considered the ultimate gold standard for confirming the
presence of toxigenic strains of C. difficile. However, it is not routinely used as a
diagnostic method because it can take up to 6 days to produce results and is not always
specific for toxin production in vivo. Thus, it is considered too time-consuming for
clinical use (2).

Cytotoxin Neutralization Assays (CNA).

Considered the traditional gold standard for

diagnosis of CDI, these tests rely upon cell culture to detect the presence of toxin B and
are generally considered to be relatively sensitive and specific (2). However, there is a
great deal of variability in methodology depending upon whether or not a commercial
assay is used, which cell line is employed, lab technician expertise and subjectivity in
reading cell culture for cytopathic effects, and the starting dilution at which the stool
samples are tested (31). In one recent study, a commonly used commercial assay
(Wampole C. difficile Toxin B test; TechLab, Blacksburg, VA) was reported to have a
sensitivity of 67.2% in comparison to toxigenic culture (32). In addition, it can take up to
48 hours to achieve results if the method is used alone and not in a two-step method.
Because of the level of expertise required, CNA is only used by a minority of clinical
laboratories.

Enzyme-linked immunosorbent assays (ELISA). For detection of toxins A and B, ELISAs
are the most commonly employed tests for detection of CDI because they are relatively
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cheap and quick to perform, achieving results within two hours if carried out upon
immediate receipt of a stool sample. The most popular commercially available assays
detect both toxin A and toxin B. A recent review by Planche and colleagues of 6
different toxin ELISAs in 18 separate studies revealed that median sensitivities of these
assays ranged from 76-95% and the median specificities were 93-100%. They estimated
the positive predictive value (PPV) of the various tests based upon hypothetical disease
prevalence. For disease prevalence of <10% half of the assays had a PPV <80%, with
that value drastically reduced with decreasing prevalence (33). At Yale-New Haven
Hospital (YNHH) the disease prevalence is 10-11% based upon the number of cytotoxin
positive stools received in the lab. 3 Just as concerning with these assays is the low
negative predictive value as related to their low reported sensitivities leading to higher
rates of false negative results. From a clinical perspective, this leads to repeat testing with
minimal diagnostic yield and increased cost per patient (34, 35).

Common-antigen ELISA and Two-Step Method. The common-antigen ELISA detects the
glutamate dehydrogenase (GDH) antigen that is specific to C. difficile. It has been shown
to have a very high sensitivity (31, 36, 37), which therefore makes it an ideal screening
test to confirm the presence or absence of C. difficile. However, it does not discern
whether or not the strain is toxigenic. For this reason, this assay is commonly used in a
two-step method in which GDH antigen-negative results are clinically reported as such
and GDH antigen-positive results are reflexively tested by a toxin ELISA or cytotoxin
neutralization assay. This method achieves relatively high sensitivity and specificity and

3

This number is an overestimation because it fails to account for repeat samples from the same
patient.
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can rapidly report most samples that are negative for C. difficile, but can still take up to
48 hours to report low cytotoxin-positive results (36-38). The two-step method is
currently used for diagnosis of C. difficile at YNHH by the Clinical Virology Laboratory.

Polymerase Chain Reaction (PCR). Real-time polymerase chain reaction (RT-PCR)
assays are not widely employed for C. difficile infection because, prior to this study,
commercial kits were not available. However, in December 2008, as this study was
being completed, the Food and Drug Administration approved the first commercially
available RT-PCR assay (BD GeneOhm™ Cdiff assay, BD Diagnostics, San Diego, CA)
to directly detect the toxin B (tcdB) gene in stool to aid in the diagnosis of CDI.4 Other
studies evaluating PCR have only used in-house assays with variable gene targets, small
numbers of samples and few positive results, making their general applicability
problematic (39-45). Three prospective studies have been published to date comparing
the BD GeneOhm™ Cdiff assay, a cytotoxicity assay, and toxigenic culture (32, 46, 47).
Only one tested an ELISA toxin test in comparison (47). All reported the BD
GeneOhm™ Cdiff assay to have a higher sensitivity than the cytotoxicity assay using
toxigenic culture as the reference standard. None of the studies compared the BD
GeneOhm™ Cdiff assay to a two-step testing algorithm, which is used to cost-effectively
enhance sensitivity and specificity of C. difficile diagnosis.

Further evaluation of the BD GeneOhm™ Cdiff assay in comparison with other
commonly-utilized diagnostic methods, e.g. toxin ELISA and a two-step method, is

4

Though the BD GeneOhm™ Cdiff assay had not been FDA-approved for clinical diagnostic use at the
start of this study, the kits were made available to the author by BD for research purposes.

18
needed to assess whether or not it should be recommended for widespread clinical use.
In addition, analysis of the cost-effectiveness of the BD GeneOhm™ Cdiff assay in
contrast to other methods is an important factor for clinical applicability.

STUDY OBJECTIVES
The objective of this study was to determine if a new commercially available PCR test
would prove more sensitive and specific than standard methods for the diagnosis of CDI.
The performance of the new BD GeneOhm™ Cdiff PCR assay for detection of C.
difficile toxin B gene was compared with the two-step method currently used at YNHH
(C. Diff Chek-60™ GDH-antigen assay followed by cytotoxin neutralization), and with
Tox A/B II™ ELISA, the test method used in most U.S. hospitals. Toxigenic culture, the
„gold standard‟ test, was used to resolve discrepant results. The hypothesis was that PCR
would prove to be the most sensitive and specific test of the clinically used methods.

MATERIALS AND METHODS
Clinical Samples. Liquid or semi-solid stool samples from hospitalized patients in
YNHH submitted for C. difficile testing were entered into the study from August 2008 to
December 2008. All samples were tested within 24 hours of receipt with C. Diff Chek™60 GDH antigen ELISA, as part of the hospital‟s standard two-step diagnostic routine.
All C. difficile GDH antigen-positive with sufficient stool available, and an equivalent
number of GDH antigen-negative stools were selected on each study day. All study
samples were subsequently tested by cytotoxin neutralization, Tox A/B II™ ELISA, and
BD GeneOhm™ Cdiff PCR Assay (Figure 1).
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Figure 1. Algorithm for Testing Stool Samples

ELISA and PCR were performed by study personnel blinded to the results of the two-step
method. When ELISA or PCR could not be performed on the same day, samples were
frozen and thawed only once according to the manufacturers‟ instructions. An aliquot of
each original stool sample was saved at -70° C for further testing. Samples that did not
have all four tests positive or all four tests negative were sent for toxigenic culture,
excluding antigen-positive only samples. Discrepant samples from patients who were on
treatment for CDI at time of sample collection were excluded from analysis. Only two
samples per patient in a 7-day period were included. Repeat samples sent on the same day
were excluded.
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Two-Step Method: C. Diff Chek™ -60 and Cytotoxicity Assay. The C. Diff Chek™-60
(TechLab, Blackburg, VA) was performed according to the manufacturer‟s instructions.
Briefly, 0.05ml of specimen was transferred to 0.2 ml of specimen diluent (buffered
protein solution containing preservative5) in a 1.5 ml centrifuge tube, vortexed and then
centrifuged at 5000 x g for 10 minutes. To the test microwells, 0.5 ml of conjugate
solution was added, after which 0.1 ml of centrifuged specimen was added. 6To the
positive control well 0.1 ml of positive control (GDH-antigen) was added and to the
negative control well 0.1 ml of diluent was added. The wells were covered and incubated
for 50 minutes at 37 C and then they were washed in an automated washer for 7 cycles
with 0.35 mL wash solution (phosphate-buffered saline and detergent). After ensuring no
residual liquid was remaining, 0.1 ml of substrate (tetramethylbenzidine and peroxide)
were added to each well and incubated at room temperature for 10 minutes. Then, 0.05
ml of stop solution (0.6N sulfuric acid) was added to each well and optical density
measured on a microplate reader. A positive result had an optical density of ≥0.080 and a
negative result had an optical density of < 0.080 using the spectophotometric dual
wavelength 450/620 nm. Stool samples received before 1:00 pm were tested on the same
day. Samples received after 1:00 pm were stored at 4° C and tested within 24 hours.
Stool samples positive for GDH antigen were tested by cytotoxicity assay. Stool samples
(0.5 ml) were added to 0.5 ml of phosphate-buffered saline with antibiotics (vancomycin,
gentamicin, and amphotericin B) and then vortexed, and the toxin was allowed to elute
for 5 minutes. After centrifugation for 10 min in a microcentrifuge, the supernatant was
removed and passed through a 0.45-µm-pore-size filter. Then, 20 µl of filtrate was
5
6

The preservative is 0.02% thimerosal.
The conjugate is GDH antigen-specific mouse monoclonal antibody coupled to horseradish peroxidase.
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inoculated in duplicate onto foreskin fibroblast monolayers (MRHF cells; BioWhittaker,
Walkersville, MD) in 96-well plates using serial 10-fold dilutions (1:10 to 1:10,000).
C. difficile antitoxin (20 µl; TechLab, Inc., Blacksburg, VA.) was added to one of the
duplicate wells inoculated with the 1:10 and 1:100 dilutions. Thus, after addition of
antitoxin, the final dilution in the first culture well was 1:20. Monolayers were read at
4, 24, and 48 hours after inoculation using an inverted microscope. A known positive
control, run with each assay, was required to show cytotoxicity in the expected range. A
positive result consisted of cytotoxicity that was neutralized by C. difficile antitoxin.
Results were recorded as the highest dilution showing specific cytotoxicity. All study
samples underwent the cytotoxicity assay on the same day or within 24 hours of receipt if
the sample was received after 1:00 p.m.
Toxin A/B II ELISA. Toxin A/B II ELISA

(TechLab, Blacksburg, VA) was

performed according to the manufacturer‟s instructions. Briefly, 0.05 ml of specimen was
transferred to 0.2 ml of specimen diluent (buffered protein solution with preservative) in
a 1.5 ml centrifuge tube, vortexed and then centrifuged at 5000 x g for 10 minutes. To the
test microwells, 0.5 ml of conjugate solution was added, after which 0.1 ml of centrifuged
specimen was added.7 To the positive control well 0.05 ml of positive control
(inactivated toxins A and B) was added and to the negative control well 0.05 ml of
diluent was added. The wells were covered and incubated for 50 minutes at 37 C and
then they were washed in an automated washer with 0.35 mL wash solution for 7 cycles.
After ensuring no residual liquid was remaining, 0.1 ml of substrate
7

The conjugate solution is a mouse monoclonal antibody specific for toxin A coupled to horseradish
peroxidase and goat polyclonal antibody specific for toxin B coupled to horseradish peroxidase in a protein
buffered solution.
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(tetramethylbenzidine and peroxide) were added to each well and incubated at room
temperature for 10 minutes. Then, 0.05 ml of stop solution (0.6N sulfuric acid) was added
to each well and after 2 minutes the optical density was measured on a microplate reader.
A positive result had an optical density of ≥0.080 and a negative result had an optical
density of < 0.080 using the spectrophotometric dual wavelength 450/620 nm. Samples
not tested within 24 hours of receipt were stored at -20° C and tested within 72 hours.
BD GeneOhm™ Cdiff PCR Assay . The BD GeneOhm™ Cdiff Assay (BD Diagnostics,
San Diego, CA) utilizes real-time PCR to amplify the toxin B (tcdB) gene in C. difficile
and fluorogenic target-specific hybridization probes for the identification of amplified
target DNA. The procedure was performed directly on stool specimens, according to the
manufacturer‟s instructions. A sterile cotton swab was dipped into the stool specimen and
then broken off into the sample buffer tube containing the Tris- EDTA sample
preparation buffer that was provided by the manufacturer. The suspension in the sample
buffer was vortexed at high speed for 1 min. For specimen dilution, 40 l of fresh sample
buffer was added to a lysis tube with glass beads before transfer of 10 l of sample buffer
containing the stool sample suspension. The lysis tube was vortexed for 5 min at high
speed and pulse-spinned for 10 seconds in a centrifuge. It was then incubated in a
heating block at 95°C for 5 minutes. The lysed, inactivated sample was kept on a cooling
block at 3 to 5°C until testing was performed, within 30 minutes. Sample tube and
reagent manipulations were performed under a ventilation hood, and reagent tubes were
kept on cold blocks at 3 to 5°C. Each sample from the lysis tube (3 l) was added to a
SmartCycler tube containing 25 l of the reconstituted master mix. Included in the master
mix was an Internal Control, a 333-bp DNA fragment of which only 55 bp shares
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homology with C. difficile, to detect inhibition of the PCR. Every PCR run included a
PCR-positive control (reconstituted DNA from the manufactured kit) and an uninoculated
sample buffer was used as a negative control. Following centrifugation for 10 s using a
Cepheid microcentrifuge especially adapted to fit the SmartCycler tubes, the reaction
tubes were placed in the SmartCycler I-CORE module (Cepheid, Sunnyvale, CA) and run
using Cepheid SmartCycler software with the BD GeneOhm Cdiff assay amplification
protocol. Results were automatically interpreted by the software as follows: “negative,”
no tcdB gene was detected; “positive,” the tcdB gene was detected; “unresolved,” either
the IC was inhibited or there was reagent failure; “invalid assay run,” the PCR control
(positive or negative) failed; “not determined,” there was an I-CORE module malfunction
(32). Samples with unresolved results were retested from the frozen eluate after thawing.
The remaining eluate in the lysis tubes was frozen at -70°C. The entire procedure
required about two hours, depending on the number of samples being run. All samples
not tested within 24 hours were stored at -20° C and tested within 5 days, as per
manufacturer instructions.
Toxigenic Culture. One 2 mL vial of stool from each of the 400 samples was saved and
stored at -70°C until the completion of the study, after which coded discrepant samples
were tested by toxigenic culture at Montefiore Medical Center, Bronx, NY by personnel
blinded to prior test results. Stool was treated with ethanol to kill non-spore flora, and
inoculated in parallel onto selective cycloserine-cefoxitin-fructose agar (CCFA)
supplemented with 0.1% taurocholate (Sigma, St Louis, MO) and chopped meat broth
(BD BBL™, Sparks, MD) supplemented with 0.1% taurocholate, 250 µg/ml cycloserine
and 16 µg/ml cefoxitin. If there was visible growth in the broth after 48 hrs, or at 5-7
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days (late growth), it was subjected to the Meridian™ toxin A/B EIA (Meridian
Bioscience, Cincinnati, OH). A positive result (OD >0.10) supported the detection of
toxigenic C. difficile. Colonies of growth on the agar that had the appearance of C
difficile (flat yellow colonies) were tested by PCR, using an internally-validated PCR for
the tcdC putative toxin repressor gene (5‟-TCTAGCTAATTGGTCATAAG-3‟,5‟AATAGCAAATTGTCTGAT-3‟), as well as the GDH gene (gdh) using published
primers [27]. All PCR reactions were performed using FastStart Hi-fidelity Taq PCR
reagents (Roche, Indianapolis, IN) with MgCl2 (2.5mM Mg final), on a Perkin-Elmer
2400 thermocycler, with a multiplex PCR protocol consisting of 5 min at 95 oC, followed
by 45 cycles of 94 oC x 1 min, 52 oC x 1 min and 72 oC x 2 min. PCR amplicons were
resolved on 2% agarose gels stained with ethidium bromide. A positive ~200bp band on
the tcdC PCR supported the detection of toxigenic C. difficile, and a ~750 bp gdh band
confirmed C. difficile. Specimens that did not have consistent results between the toxin
A/B ELISA from broth culture and toxin gene PCR had all discordant tests repeated; in
addition, the broth culture was subcultured onto agar to identify individual colonies
which could be analyzed by PCR. If there was a negative toxin ELISA result from broth
but PCR-positive colonies on agar, the colonies were directly inoculated into broth and
tested by toxin ELISA after 48 hrs.
Discrepant Analysis. Results were considered discrepant if 1, 2 or 3 tests were positive,
excluding GDH antigen-positive only samples. Antigen-positive only samples were
considered to represent colonization with non-toxigenic strains of C. difficile. To resolve
discrepant results, three steps were taken. First, all samples for which PCR results were
discordant with two-step results were repeated by PCR. Second, all discrepant samples
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were submitted for toxigenic culture. Lastly, chart review was conducted for all patients
with discrepant samples.
Statistical analysis. Statistical analysis was performed using McNemar‟s test, which
applies to matched pairs of dichotomous test results, e.g. when assessing the statistical
significance of the observed difference between performance characteristics of two
diagnostic tests (48).
Student Responsibilities. The author was responsible for: design of the study;
submission of HIC protocol; performing BD GeneOhm™ Cdiff PCR and Tox A/B II
assays on all stool specimens; performing chart review for all patients with discrepant
results; analyzing results; writing the first draft of the manuscript for publication;
incorporating suggestions and revisions from co-authors; and helping to revise the paper
as recommended by journal reviewers. The two-step method was performed on stool
samples by YNHH Virology technicians and toxigenic culture was performed by Paul
Riska at Montefiore Medical Center, Bronx, NY.

RESULTS
A total of 434 samples were initially tested. Of these, 18 were excluded because the
patients were found to be on treatment for CDI and 16 were excluded because there were
more than 2 samples per patient sent in a 7-day period. Four-hundred stool samples from
341 patients were included in the final analysis. Overall, 66 samples were positive by all
four tests. Of the 200 GDH-positive samples, 71 were positive by Tox A/B II, 88 were
positive by the two-step method, 96 were positive by BD GeneOhm™ Cdiff assay, and
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96 were positive by GDH antigen only. For the 88 cytotoxin-positive samples in this
study, 29 (33.0%) were positive at 4 hrs, 48 (54.5%) at 24 hrs, and 11 (12.5%) at 48 hrs.
Six of the 11 positive at 48 hrs were positive only at the 1:20 starting dilution. Of 200
GDH-negative samples, 3 were positive by PCR only and 197 were negative for all four
tests. Results are shown in Table 1. Two of 400 samples (0.5%) were initially
unresolved by PCR but became negative upon repeat testing.

Forty-one of the samples were considered discrepant (Table 1) and were cultured. Thirtynine of these were toxigenic culture-positive, and 2 were culture-negative. Fifteen
cytotoxin-negative samples were GDH antigen and PCR-positive and 3 were PCRpositive only. All of these 18 were toxigenic culture positive (true positives). Twelve of
41 discrepant samples were negative by Tox A/B II and positive by all other tests,
including toxigenic culture. Ten discrepant samples were cytotoxin-positive and PCRnegative and 9 were found to be toxigenic culture positive for C. difficile. Two of the 9
eluates, stored at -70oC, were found to be PCR-positive upon re-testing. Eight of the 9
toxigenic culture-positive samples had a very low yield of bacteria on agar culture (1+ or
fewer by a semi-quantitative scoring system). Five of the 9 PCR-negative samples were
cytotoxin positive at 4 or 24 hrs, and 4 were positive at 48 hrs. Chart reviews of the 9
cytotoxin-positive, PCR–negative patients revealed multiple prior or subsequent C.
difficile cytotoxin-positive stools in 4 (44.4%) of these 9 patients. Of the remaining two
toxigenic culture negative samples, one was GDH antigen and Tox A/B II-positive and
the other was positive by GDH antigen and cytotoxin at 1:10 dilution only. These were
designated false positives.

Table 1. Results showing discrepants
No. Initial GDH Ag Cytotoxicity Tox A/B PCR
Pos Testsa
EIA
Assay
ELISA

No. with
initial resultsb

No. pos. by
toxigenic culture

No. neg. by
No. true positivesc
toxigenic culture

4

+

+

+

+

66

Not done

Not done

66

1

+

-

-

-

96

Not done

Not done

0

0

-

-

-

-

197

Not done

Not done

0

3

+

+

+

-

4

4

0

4

3

+

+

-

+

12

12

0

12

2

+

+

-

-

6

5

1

5

2

+

-

-

+

15

15

0

15

2

+

-

+

-

1

0

1

0

1

-

-

-

+

3

3

0

3

TOTAL

200

88

71

96

400

39

2

105

a, This column represents the number of tests for which any given sample was positive. For example, a sample with 4 tests positive tested positive for GDHantigen EIA and cytotoxin neutralization assay (two-step method), Tox A/B II ELISA and PCR.
b. In total, 41 discrepant samples were tested by toxigenic culture and 39 were positive
c. A sample was considered a true positive if either all 4 tests were positive or if it was toxigenic culture positive.
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At the time of the study, the BD GeneOhm™ Cdiff assay was not an FDA-cleared test, so
PCR results were not clinically reported. Chart review was conducted on patients with
samples that were PCR-positive but cytotoxin-negative. Eight PCR-positive, cytotoxinnegative patients were treated for CDI for a median of 1.5 days until the negative
cytotoxin result was reported, and then treatment was stopped. Ten patients received no
treatment. Only 5 of the 18 PCR-positive, cytotoxin-negative patients had additional
testing in 6-8 months of follow-up and only one of these had a subsequent cytotoxin
positive sample (22 days after the sample included in the study).

The results and performance characteristics of all tests after resolution of discrepants by
toxigenic culture are given in Table 2. After culture resolution, Tox A/B II detected 70
(66.7%), the two-step method detected 87 (82.9%), and PCR detected 96 (91.4%) of 105
true positives. There was a 93.0% concordance of PCR with the two-step method and a
91.3% concordance of PCR with the Tox A/B II. The sensitivity, specificity, positive
predictive value and negative predictive values as compared to toxigenic culture for BD
GeneOhm™ Cdiff assay are 91.4%, 100%, 100% and 97%, respectively; for the two-step
method are 82.9%, 99.7%, 98.9% and 94.2%, respectively; and for Tox A/B II ELISA are
66.0%, 99.7%, 98.6% and 89.4%, respectively.
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Table 2. Comparison of GeneOhm Cdiff Real-time PCR assay, a two-step algorithm
and Tox A/B II ELISA after resolution of discrepant results by toxigenic culture

Assay

No. with result after
resolution by
toxigenic culturea

Performance characteristics of assay b

Positive

Sensitivity Specificity PPVc NPVd
(%)
(%)
(%) (%)

Negative

GeneOhm
RT-PCRe
Positive

96
105

87

Negative 18
Total

105

70

Negative 35
Total

105

97.0

82.9

99.7

98.9

94.2

66.0

99.7

98.6

89.4

295

1
294
295

Tox A/B II
ELISA
Positive

100

295

Two-step
algorithm
Positive

100

0

Negative 9
Total

91.4

1
294
295

a. Samples with discrepant results were resolved by toxigenic culture.
b. Calculations make the assumption that samples with all tests positive would be toxigenic culture-positive
and samples that are either GDH antigen-only positive or negative by all tests would be toxigenic culturenegative. Only a subset of GDH-negative samples were tested.
c. Positive predictive value
d. Negative predictive value
e. The difference between PCR and the two-step algorithm was not significant (p=0.1237). The difference
between PCR and Tox A/B II ELISA was significant (p < 0.0001). McNemar‟s test.
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The average turnaround times and materials cost per test in our laboratory, based on
5,000 samples a year are given in Table 3. The BD GeneOhm™ Cdiff assay is the most
expensive at $25.83 per test with the two-step method, Tox A/B II ELISA, and
cytotoxicity assay following in order of decreasing cost for materials per test.

Table 3. Comparison of time to result and materials costs for different methods
Turnaround Time

Materials cost per testa

BD GeneOhm™ Cdiff assay

2-24 hrs

$25.83

Tox A/B II ELISA

2-24 hrs

$4.12

Two-Step (GDH /
Cytotoxicity Algorithm)b

6-48 hrs

$5.02

Cytotoxicity assay onlyc

4-48 hrs

$3.97

Test

a, Actual costs in our laboratory. Labor, controls, repeats, are not included.
b, With the 2-step method, GDH antigen-negatives are reported within 2-24 hrs. GDH-positives are tested
for cytotoxin, and cytotoxin results are reported after 4, 24 and 48 hrs of incubation.
c, Cytotoxin positives are reported at 4, 24 and 48 hrs, and all negatives are reported at 48 hrs.

DISCUSSION
This is the first study comparing the performance characteristics of the commercial BD
GeneOhm™ Cdiff assay to Tox A/B II and the two-step GDH antigen ELISA/cytotoxin
protocol for diagnosis of CDI. The BD GeneOhm™ Cdiff assay was significantly more
sensitive than the Tox A/B II (91.4% vs. 66.0% respectively, p <0.0001). There was an
absolute increase in the number of true positives detected by BD GeneOhm™ Cdiff assay
as compared to the two-step method (91.4% vs. 82.9%, respectively), but the difference
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was not statistically significant in our study (p=0.1237). The concordance of the BD
GeneOhm™ Cdiff assay with the two-step method (93.0%) is similar to that of BD
GeneOhm™ Cdiff assay with the cytotoxicity assay as reported by Stamper, et al
(94.8%), Barbut et al (92%) and Terhes, et al (92.6%) (32, 46, 47).

All 18 two-step negative, PCR positive discrepant samples in our study were toxigenic
culture positive. In contrast, Stamper et al (32) reported that 6 of 17 (35.3%) PCRpositive, cytotoxin-negative samples failed to yield toxigenic C. difficile on culture.
Terhes, et al, (47) similarly reported 17 cytotoxin negative, PCR positive samples that
were toxigenic culture positive and only 5 that were toxigenic culture negative. While
this could reflect differences in the culture methods used, further study is merited.

Since PCR results were not clinically reported during our study, the 18 PCR-positive
samples were reported as C. difficile negative and patients received brief empiric
treatment or no treatment for CDI, with no apparent adverse consequences. Only one
(5.5%) of 18 patients had subsequent C. difficile disease 22 days later. This highlights a
concern for highly sensitive molecular amplification tests that target toxin genes, rather
than in vivo toxin production. Patients may be colonized with toxigenic C. difficile but
have diarrhea due to other causes. There is evidence that carriers of toxigenic C.
difficile, who may be inadvertently identified by PCR due to inappropriate sample
submission, may have immune mechanisms, which abrogate the toxin effects of their
strain (4, 49, 50). The effects of eradicating asymptomatic carriage by antibiotics on the
immune response of the carrier are not known. Thus, clinical correlation is even more
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essential for accurate diagnosis of CDI in patients diagnosed by PCR to avoid treating
patients unnecessarily (43).

It is also possible that these PCR-identified cases have low-titers of toxin production that
are below the detection limits of ELISA toxin tests or cytotoxin neutralization assays.
These cases might represent a small pathogen burden. In the 15-23% of CDI patients
with mild disease, the symptoms may be cleared by simply removing the inciting
antibiotics (22). However, these patients may still be at risk of spreading C. difficile
spores in the hospital setting, because they test „negative‟ by conventional methods, and
are neither isolated nor treated. In theory, if these cases are detected by PCR, isolated
and/or treated, nosocomial transmission to other more susceptible patients could be
reduced. It is unclear whether or not these benefits would outweigh the costs of detecting,
isolating and treating an increased number of patients with mild disease, and warrants
further study.

There is some evidence to suggest correlation between host humoral immune response
and severity of CDI, as mentioned previously. One study showed higher levels of
antitoxin A immunoglobulin G in asymptomatic carriers of C. difficile than in those who
developed symptomatic diarrhea (4). A later study identified a polymorphism in the
interleukin-8 (IL-8) promoter gene that was associated with higher serum and fecal levels
of IL-8 in hospitalized patients with C. difficile –associated diarrhea (CDAD) than with
hospitalized controls with non-C. difficile diarrhea and without diarrhea (49). Higher IL8 levels in patients were subsequently correlated with impaired levels of immunoglobulin
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G to toxin A and thus enhanced susceptibility to CDAD as compared to two control
groups (50). These studies support the possibility that patients who are carriers or have
self-resolving, mild CDAD might have a higher level of immune response contributing to
the limitation of illness. However, patients who fail to mount a significant immune
response could potentially develop more severe disease manifestations from the same
organism. Hypothetically, this would justify treating milder cases of CDAD that are
cytotoxin negative but PCR positive. However, it should also be noted that identification
of these additional patients by PCR will increase costs of isolation and prolong
hospitalization. The costs and benefits of treatment for these patients merit further study.

Although PCR detected more positives than other methods in this study, 10 samples were
two-step method positive and PCR-negative. Nine of these 10 samples yielded toxigenic
C. difficile in culture and one was culture negative. Chart reviews of the 9 cytotoxinpositive, PCR–negative patients revealed multiple prior or subsequent C. difficile
cytotoxin-positive stools in 4 (44.4%) of these 9 patients. Eight of the 9 toxigenic
culture-positive samples had a very low yield of bacteria on agar culture (1+ or fewer by
a semi-quantitative scoring system) and thus may have been below the detection limit of
the PCR assay. This could have been due to poor initial sample quality. On retesting of
the frozen PCR lysates, 2 of the 10 two-step positive/PCR negative samples were PCR
positive on repeat, implying some degree of inhibition or sampling variability on initial
testing. The one sample that was two-step method positive, but toxigenic culturenegative, had a low toxin titer of 1:20 at 48 hours. This was considered a false positive
cytotoxin result.
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Stamper et al (32) reported only one cytotoxin-positive, toxigenic culture-positive sample
missed by PCR, Terhes et al (47) reported two, and Barbut et al (46) reported none. This
difference might be explained by differences in cytotoxin testing methods. Cytotoxicity
testing in our institution is performed by Virology Laboratory personnel, using freshly
prepared human fibroblast cell culture plates, starting at a lower final dilution than most
laboratories (1:20) with serial 10-fold dilutions of sample, and read at 4, 24 and 48 hours,
with almost 90% of positives reported within 4-24 hours. Thus, our cytotoxin results
may be superior to those obtained using higher starting dilutions of 1:50 (32) or 1:100
(46) using commercially prepared cell culture, and the BD GeneOhm™ Cdiff assay
might perform even better compared to commercial cytotoxin neutralization. This
reasoning applies as well to the methods for cytotoxicity assay employed by Terhes et al
(47), which was initially evaluated in comparison to the BD GeneOhm™ Cdiff assay, but
also used as part of their gold standard to verify toxigenicity of bacterial cultures. They
utilized a HeLa cell line for cell culture, which has been shown to have a 10-fold lower
sensitivity than other cell lines such as human fibroblasts used by the Yale Virology
Laboratory. In addition, their cytotoxicity assay was performed up to 5 days after the
receipt of the stool specimen, which may permit toxin degradation (51). The
aforementioned factors are likely to greatly reduce the sensitivity of their cytotoxicity
assay and, by comparison, make the performance of the BD GeneOhm™ Cdiff assay
appear artificially elevated. They report a sensitivity and specificity of 96.4% and 99.1%
respectively (47), as compared to 83.6% and 98.2%, respectively, by Stamper et al (32)
and 91.4% and 100.0%, respectively, in our study.
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Nevertheless, the failure of PCR to detect 9 true positives detected by the two-step
method was a concern. It is unlikely that the BD GeneOhm Cdiff assay PCR failed to
detect these 9 samples due to inhibitors for several reasons. First, each reaction mix has
an internal amplification control to monitor reagent integrity and PCR inhibition.
Inhibitory samples have an internal control result of “FAIL” and a BD GeneOhm Cdiff
assay result of “Unresolved”. The 9 samples passed the test for internal control
amplification. Secondly, eight of the nine samples had very low yield of C. difficile in
direct anaerobic culture, with <10 cfu8 recovered for 5 of those samples. In addition, two
of the stool samples were positive on repeat testing of the sample lysates, suggesting
sample variability in the runs. These findings support the idea that the inability of the BD
GeneOhm Cdiff assay to detect these samples was more likely due to a bacterial load
below the level of detection of the assay, suggesting that dilution of the samples will not
likely improve PCR detection. The quality of the stool sample at initial collection is
more likely to be the source of low bacterial load.

In addition to low numbers of bacteria and presence of inhibitors, another possible
explanation for the failure of the BD GeneOhm™ Cdiff assay to detect samples that were
positive by the two-step method is genetic variance at the tcdB locus, leading to
mismatch of PCR primers. While the majority of isolates of toxigenic C. difficile come
from toxinotype variants with an intact tcdB gene, mutations and deletions in tcdB have
been documented (12, 52). A recent study discovered a genotype of a binary toxinproducing C. difficile strain that contained the toxin A and binary toxin genes, but was
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negative for the toxin B gene (53). This strain is genetically distinct from the epidemic
BI/NAP1/027 strain. However, reports of such toxigenic C. difficile variants are very
rare, as toxin B appears to be an essential virulence factor (54). Preliminary unpublished
data from Paul Riska shows that, in testing over 70 isolates of each type, the BD
GeneOhm PCR is equally efficient at detecting the current North American epidemic
(ribotype 27) and non-epidemic strains. However, monitoring for evolution of new
variants of tcdB is warranted.

The Tox A/B II ELISA failed to detect 35 toxigenic culture-positive samples and yielded
one false positive result, consistent with the documented low sensitivities of this class of
tests (33, 55). Cytotoxin neutralization as performed in our virology laboratory, detected
9 true positives missed by PCR. However, due to the techniques employed at YNHH
mentioned above to maximize sensitivity of the cytotoxicity assay, it may be that our lab
is an outlier in the quality of this test. Other labs that solely utilize an ELISA toxin assay
or a commercial cytotoxin neutralization assay with much lower sensitivity than ours
could be missing many true positive cases of CDI that would be detected by the BD
GeneOhm™ Cdiff assay.

The BD GeneOhm™ Cdiff assay was simple to perform and produced results in
approximately 2 hours, compared to 2 hours for the Tox A/B II ELISA and 6-48 hours
for the two-step method (Table 3). The PCR method is more expensive than other
methods, but may reduce nosocomial transmission of toxigenic C. difficile, and thus lead
to long-term savings for hospitals and patients. Of note, the costs for each test will vary

37
among institutions depending on test volume, contracts with suppliers, and other factors.
In our virology laboratory, cytotoxin neutralization is an inexpensive test. Thus, to test
5,000 samples a year using BD GeneOhm™ Cdiff assay as the sole assay will cost an
additional $100,000 in reagents, which is a significant barrier to implementation. In
addition, the increased number of cases detected per year by PCR will require isolation
and treatment, resulting in increased hospital costs over the short term. Yet, in the longterm, these costs could be offset by reduction in the overall rates of transmission of C.
difficile spores if more „true positives‟ are isolated and treated. Moreover, more rapid
diagnosis of cases would result in earlier isolation and presumably decreased nosocomial
transmission. For instance, at YNHH the two-step diagnostic algorithm can take up to 48
hours to receive a positive result for CDI, during which time the patient is not placed on
isolation precautions. If PCR were used a positive result theoretically would be available
within hours 2- 24 hours after the sample was submitted to the lab.

Chart review of patients with discrepant samples revealed hospital-wide problems with
stool sample submission for C. difficile analysis, including submission of samples from
patients with minimal diarrhea, from patients who were already on treatment, and
multiple samples from the same patient on the same day or within a 7-day period. Though
discordant samples from patients found to be on therapy were excluded from analysis in
the study, these problems were illustrative of inappropriate clinical use of the test, which
ultimately drives up overall health care costs. To both avoid unnecessary treatment and
reduce costs of PCR testing, clinicians will need to be educated about limiting C. difficile
testing to patients with a reasonable probability of having disease, such as those patients
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having 3 or more loose stools per day for 1 to 2 days (43). Moreover, clinicians should
not be ordering C. difficile testing for patients who are undergoing antibiotic treatment for
CDI as this can interfere with the toxin gene expression and increase the likelihood of
false negative test results. Utilization of automatic clinician reminders or „pop-up‟
windows through computerized electronic ordering systems would be one way to reduce
inappropriate ordering of these tests, and thus decrease overall costs associated with the
disease.

There were several limitations of this study. Only the discrepant samples were cultured
and not all samples tested were included in the study. The performance characteristics of
the various assays were compared to toxigenic culture as a gold standard, with the
assumption made that samples for which all four tests were positive would be toxigenic
culture-positive and those for which all four tests were negative would be toxigenic
culture-negative. All GDH-antigen positive samples submitted on study days that met
study criteria, but only a subset of GDH-antigen negative samples, were included. In
addition, samples were sent to a separate institution for toxigenic culture and different
assays were used to determine whether strains of C. difficile were toxigenic. Specifically,
a Meridian toxin A/B EIA and an in-house PCR assay to detect tcdC (toxin repressor
gene) were utilized, rather than the TechLab toxin A/B ELISA and the tcdB-based PCR
assay used in the initial analysis. Thus, some of the divergent results may be due to
different performance attributes of these particular assays. However, it is likely that a
greater difference was attributable to the fact that the toxigenic culture assays were
applied to an amplified culture rather than a crude stool sample.
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In conclusion, the BD GeneOhm™ Cdiff assay is the first FDA-approved commercial
PCR kit for diagnosis of toxigenic C. difficile and could be a promising new tool. This
study found it to be much more sensitive than a common ELISA toxin test for diagnosis
of toxigenic C. difficile, which is the most widely used class of diagnostic assay for C.
difficile infection, yet typically has poor sensitivities. The BD GeneOhm™ Cdiff assay is
as sensitive and specific as a two-step method, currently used at YNHH. It is more
expensive, but has a faster turnaround time than the two-step method, which could lead to
earlier diagnosis of CDI and reduction of nosocomial transmission, hypothetically
resulting in overall cost savings. A potential concern is increased treatment of
asymptomatic carriers or mild, self-resolving disease. This study also found inappropriate
utilization of the two-step method to be quite common at YNHH, including ordering the
test multiple times for one patient on the same day or within a 7-day period, and when the
patient was being treated for CDI. The implementation of any diagnostic test should be
accompanied by education of clinicians about appropriate use of the test and
interpretation of its results
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